TN2013000400A1 - Imidazopyridazines as akt kinase inhibitors - Google Patents

Imidazopyridazines as akt kinase inhibitors

Info

Publication number: TN2013000400A1
Authority: TN; Tunisia
Prior art keywords: imidazopyridazines; kinase inhibitors; akt kinase; akt; inhibitors
Prior art date: 2011-04-07

Application number

TNP2013000400A

Other languages

English (en)

Inventor

Ulf Bömer

Lars Bärfacker

William Johnston Scott

Andrea Hägebarth

Stuart Ince

Hartmut Rehwinkel

Oliver Politz

Roland Neuhaus

Hans Briem

Original Assignee

Bayer Ip Gmbh

Bayer Pharma AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-04-07

Filing date

2013-10-03

Publication date

2015-03-30

2013-10-03 Application filed by Bayer Ip Gmbh, Bayer Pharma AG filed Critical Bayer Ip Gmbh

2015-03-30 Publication of TN2013000400A1 publication Critical patent/TN2013000400A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Pregnancy & Childbirth (AREA)
Gynecology & Obstetrics (AREA)
Reproductive Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Cosmetics (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)

TNP2013000400A 2011-04-07 2013-10-03 Imidazopyridazines as akt kinase inhibitors TN2013000400A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201161472732P	2011-04-07	2011-04-07
PCT/EP2012/056300 WO2012136776A1 (fr)	2011-04-07	2012-04-05	Imidazopyridazines en tant qu'inhibiteurs de la kinase akt

Publications (1)

Publication Number	Publication Date
TN2013000400A1 true TN2013000400A1 (en)	2015-03-30

Family

ID=45953129

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2013000400A TN2013000400A1 (en)	2011-04-07	2013-10-03	Imidazopyridazines as akt kinase inhibitors

Country Status (43)

Country	Link
US (2)	US9206185B2 (fr)
EP (1)	EP2694510B1 (fr)
JP (1)	JP5906303B2 (fr)
KR (1)	KR20140022057A (fr)
CN (1)	CN103596957B (fr)
AP (1)	AP3597A (fr)
AR (1)	AR087148A1 (fr)
AU (1)	AU2012238589B2 (fr)
BR (1)	BR112013025777A2 (fr)
CA (1)	CA2832374A1 (fr)
CL (1)	CL2013002878A1 (fr)
CO (1)	CO6862145A2 (fr)
CR (1)	CR20130515A (fr)
CU (1)	CU24263B1 (fr)
CY (1)	CY1117163T1 (fr)
DK (1)	DK2694510T3 (fr)
DO (1)	DOP2013000226A (fr)
EA (1)	EA024890B1 (fr)
EC (1)	ECSP13013008A (fr)
ES (1)	ES2558780T3 (fr)
GT (1)	GT201300238A (fr)
HR (1)	HRP20160011T1 (fr)
HU (1)	HUE026323T2 (fr)
IL (1)	IL228567A0 (fr)
JO (1)	JO3068B1 (fr)
MA (1)	MA35016B1 (fr)
ME (1)	ME02316B (fr)
MX (1)	MX336865B (fr)
NI (1)	NI201300105A (fr)
PE (1)	PE20141380A1 (fr)
PH (1)	PH12013502073A1 (fr)
PL (1)	PL2694510T3 (fr)
PT (1)	PT2694510E (fr)
RS (1)	RS54480B1 (fr)
SG (1)	SG193631A1 (fr)
SI (1)	SI2694510T1 (fr)
SM (1)	SMT201600001B (fr)
TN (1)	TN2013000400A1 (fr)
TW (1)	TWI535719B (fr)
UA (1)	UA111739C2 (fr)
UY (1)	UY34006A (fr)
WO (1)	WO2012136776A1 (fr)
ZA (1)	ZA201307223B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL2303021T3 (pl)	2008-06-16	2019-10-31	Univ Tennessee Res Found	Związki do leczenia nowotworu
US9029408B2 (en)	2008-06-16	2015-05-12	Gtx, Inc.	Compounds for treatment of cancer
US9447049B2 (en)	2010-03-01	2016-09-20	University Of Tennessee Research Foundation	Compounds for treatment of cancer
RU2581367C2 (ru)	2010-03-01	2016-04-20	Джи Ти Икс, ИНК.	Соединения для лечения рака
US11084811B2 (en)	2010-03-01	2021-08-10	Oncternal Therapeutics, Inc.	Compounds for treatment of cancer
PH12013502073A1 (en) *	2011-04-07	2014-01-13	Bayer Ip Gmbh	Imidazopyridazines as akt kinase inhibitors
JP6106694B2 (ja) *	2012-01-10	2017-04-05	バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＧｍｂＨ	Ａｋｔキナーゼ阻害剤としての置換ピラゾロピリミジン類
EP2802586B1 (fr) *	2012-01-10	2016-05-25	Bayer Intellectual Property GmbH	Imidazopyrazines substituées comme inhibiteurs de kinase akt
EP2925299B1 (fr) *	2012-11-30	2018-06-06	Novartis AG	Nouvelle composition pharmaceutique
CN105163584B (zh) *	2013-03-05	2019-06-04	田纳西大学研究基金会	用于治疗癌症的化合物
WO2014158467A1 (fr) *	2013-03-12	2014-10-02	Glaxosmithkline Llc	Combinaison
AU2014236348B2 (en) *	2013-03-14	2018-05-10	Epizyme, Inc.	Combination therapy for treating cancer
JP2017503809A (ja) *	2014-01-09	2017-02-02	バイエル・ファルマ・アクティエンゲゼルシャフト	アミド置換イミダゾピリダジン
WO2018098411A1 (fr) *	2016-11-28	2018-05-31	Bristol-Myers Squibb Company	Inhibiteurs de gsk-3
EP3453706A1 (fr)	2017-09-08	2019-03-13	Basf Se	Composés pesticides de l'imizazole
GB2600384A (en)	2020-09-30	2022-05-04	Vaderis Therapeutics Ag	Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL150368A0 (en)	1999-12-23	2002-12-01	Nitromed Inc	Nitrosated and nitrosylated cyclooxygenase-2-inhibitors, compositions and methods of use
US6908929B2 (en)	2000-03-31	2005-06-21	Ortho-Mcneil Pharmaceutical, Inc.	Phenyl-substituted imidazopyridines
KR100830859B1 (ko)	2000-04-27	2008-05-21	아스텔라스세이야쿠 가부시키가이샤	이미다조피리딘 유도체 및 이를 함유하는 의약 조성물
JP2006520796A (ja)	2003-03-17	2006-09-14	タケダサンディエゴインコーポレイテッド	ヒストンデアセチラーゼインヒビター
AU2004233828B2 (en)	2003-04-24	2009-05-28	Merck Sharp & Dohme Corp.	Inhibitors of Akt activity
ZA200601706B (en)	2003-07-30	2007-09-26	S A L V A T Lab Sa	Substituted imidazopyrimidines for the prevention and treatment of cancer
AU2005233584B2 (en)	2004-04-09	2010-12-09	Merck Sharp & Dohme Corp.	Inhibitors of Akt activity
AU2005290081B2 (en)	2004-08-23	2010-12-02	Merck Sharp & Dohme Corp.	Inhibitors of Akt activity
EP1786780A1 (fr)	2004-08-24	2007-05-23	Basf Aktiengesellschaft	Sulfites d'imidazolium-methyle utilises comme composes de depart ausgangsverbindungen pour la production de liquides ioniques
AU2005316826A1 (en)	2004-12-15	2006-06-22	Merck Sharp & Dohme Corp.	Inhibitors of Akt activity
MX2007014510A (es)	2005-05-20	2008-02-05	Array Biopharma Inc	Compuestos inhibidores de raf y metodos de uso de los mismos.
ES2409168T3 (es)	2005-06-10	2013-06-25	Merck Sharp & Dohme Corp.	Inhibidores de la actividad Akt
WO2007025090A2 (fr)	2005-08-25	2007-03-01	Kalypsys, Inc.	Inhibiteurs de kinase mapk/erk
PE20070978A1 (es)	2006-02-14	2007-11-15	Novartis Ag	COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
US7530313B2 (en)	2006-05-12	2009-05-12	Day & Zimmerman, Inc.	Self-destruct fuze delay mechanism
AR064010A1 (es)	2006-12-06	2009-03-04	Merck & Co Inc	Inhibidores de la actividad de la akt
CN101790526A (zh) *	2007-06-08	2010-07-28	雅培制药有限公司	用作激酶抑制剂的5-杂芳基取代的吲唑化合物
CA2694058C (fr)	2007-08-14	2016-06-07	Bayer Schering Pharma Aktiengesellschaft	Pyrimidines bicycliques condensees
EA201000297A1 (ru)	2007-08-14	2010-08-30	Байер Шеринг Фарма Акциенгезельшафт	Конденсированные бициклические имидазолы
US20100331333A1 (en)	2007-12-21	2010-12-30	Wyeth Llc	Imidazo [1,2-B] Pyridazine Compounds
WO2009148916A1 (fr)	2008-06-03	2009-12-10	Merck & Co., Inc.	Inhibiteurs de l'activité akt
MX2010013224A (es)	2008-06-03	2010-12-21	Merck Sharp & Dohme	Inhibidores de la actividad de la serina/treonina cinasa.
AR074072A1 (es)	2008-11-11	2010-12-22	Lilly Co Eli	Compuesto de imidazol -piperidin -pirrol-pirimidin-6-ona, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar el glioblastoma multiforme
PA8854101A1 (es)	2008-12-18	2010-07-27	Ortho Mcneil Janssen Pharm	Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa
AU2010208480A1 (en)	2009-02-02	2011-07-28	Msd K.K.	Inhibitors of Akt activity
AU2010213192A1 (en) *	2009-02-13	2011-08-04	Bayer Intellectual Property Gmbh	Fused pyrimidines
WO2010104933A1 (fr)	2009-03-11	2010-09-16	Merck Sharp & Dohme Corp.	Inhibiteurs de l'activité akt
US8691825B2 (en)	2009-04-01	2014-04-08	Merck Sharp & Dohme Corp.	Inhibitors of AKT activity
AR076936A1 (es)	2009-06-02	2011-07-20	Vitae Pharmaceuticals Inc	Inhibidores de carbamato y urea de la 11 beta hidroxiesteroide deshidrogenasa 1
WO2011033265A1 (fr)	2009-09-18	2011-03-24	Almac Discovery Limited	Composés pharmaceutiques
ES2552841T3 (es)	2010-07-12	2015-12-02	Bayer Intellectual Property Gmbh	Imidazo[1,2-a]pirimidinas y -piridinas sustituidas
ES2539257T3 (es)	2010-07-28	2015-06-29	Bayer Intellectual Property Gmbh	Imidazo[1,2-b]piridazinas sustituidas
PH12013502073A1 (en) *	2011-04-07	2014-01-13	Bayer Ip Gmbh	Imidazopyridazines as akt kinase inhibitors

2012
- 2012-04-05 PH PH1/2013/502073A patent/PH12013502073A1/en unknown
- 2012-04-05 US US14/007,427 patent/US9206185B2/en not_active Expired - Fee Related
- 2012-04-05 MX MX2013011699A patent/MX336865B/es active IP Right Grant
- 2012-04-05 EP EP12713963.2A patent/EP2694510B1/fr active Active
- 2012-04-05 CN CN201280027994.5A patent/CN103596957B/zh not_active Expired - Fee Related
- 2012-04-05 MA MA36290A patent/MA35016B1/fr unknown
- 2012-04-05 ES ES12713963.2T patent/ES2558780T3/es active Active
- 2012-04-05 DK DK12713963.2T patent/DK2694510T3/en active
- 2012-04-05 CA CA2832374A patent/CA2832374A1/fr not_active Abandoned
- 2012-04-05 AU AU2012238589A patent/AU2012238589B2/en not_active Ceased
- 2012-04-05 SG SG2013072509A patent/SG193631A1/en unknown
- 2012-04-05 PE PE2013002192A patent/PE20141380A1/es not_active Application Discontinuation
- 2012-04-05 PL PL12713963T patent/PL2694510T3/pl unknown
- 2012-04-05 RS RS20160005A patent/RS54480B1/sr unknown
- 2012-04-05 JO JOP/2012/0084A patent/JO3068B1/ar active
- 2012-04-05 HR HRP20160011TT patent/HRP20160011T1/hr unknown
- 2012-04-05 ME MEP-2016-1A patent/ME02316B/me unknown
- 2012-04-05 JP JP2014503153A patent/JP5906303B2/ja not_active Expired - Fee Related
- 2012-04-05 BR BR112013025777A patent/BR112013025777A2/pt active Search and Examination
- 2012-04-05 CU CUP2013000135A patent/CU24263B1/es unknown
- 2012-04-05 PT PT127139632T patent/PT2694510E/pt unknown
- 2012-04-05 SI SI201230430T patent/SI2694510T1/sl unknown
- 2012-04-05 HU HUE12713963A patent/HUE026323T2/en unknown
- 2012-04-05 WO PCT/EP2012/056300 patent/WO2012136776A1/fr not_active Ceased
- 2012-04-05 KR KR1020137029229A patent/KR20140022057A/ko not_active Withdrawn
- 2012-04-05 EA EA201301130A patent/EA024890B1/ru not_active IP Right Cessation
- 2012-04-05 AP AP2013007215A patent/AP3597A/xx active
- 2012-04-06 TW TW101112356A patent/TWI535719B/zh not_active IP Right Cessation
- 2012-04-09 UY UY0001034006A patent/UY34006A/es not_active Application Discontinuation
- 2012-04-09 AR ARP120101200A patent/AR087148A1/es unknown
- 2012-05-04 UA UAA201312894A patent/UA111739C2/uk unknown
2013
- 2013-09-26 ZA ZA2013/07223A patent/ZA201307223B/en unknown
- 2013-09-29 IL IL228567A patent/IL228567A0/en unknown
- 2013-10-03 TN TNP2013000400A patent/TN2013000400A1/fr unknown
- 2013-10-07 GT GT201300238A patent/GT201300238A/es unknown
- 2013-10-07 DO DO2013000226A patent/DOP2013000226A/es unknown
- 2013-10-07 CL CL2013002878A patent/CL2013002878A1/es unknown
- 2013-10-07 CO CO13237923A patent/CO6862145A2/es active IP Right Grant
- 2013-10-07 NI NI201300105A patent/NI201300105A/es unknown
- 2013-10-07 CR CR20130515A patent/CR20130515A/es unknown
- 2013-11-04 EC ECSP13013008 patent/ECSP13013008A/es unknown
2015
- 2015-07-06 US US14/792,205 patent/US9604989B2/en not_active Expired - Fee Related
2016
- 2016-01-05 SM SM201600001T patent/SMT201600001B/it unknown
- 2016-01-08 CY CY20161100011T patent/CY1117163T1/el unknown

Also Published As

Publication number	Publication date
CL2013002878A1 (es)	2014-05-02
TW201245204A (en)	2012-11-16
AR087148A1 (es)	2014-02-26
TWI535719B (zh)	2016-06-01
PL2694510T3 (pl)	2016-03-31
HUE026323T2 (en)	2016-05-30
JP5906303B2 (ja)	2016-04-20
US20150368250A1 (en)	2015-12-24
JO3068B1 (ar)	2017-03-15
MX336865B (es)	2016-02-04
PH12013502073A1 (en)	2014-01-13
CY1117163T1 (el)	2017-04-05
ECSP13013008A (es)	2013-12-31
PT2694510E (pt)	2016-02-08
ZA201307223B (en)	2014-12-23
IL228567A0 (en)	2013-12-31
PE20141380A1 (es)	2014-10-18
AU2012238589A1 (en)	2013-11-07
ME02316B (me)	2016-06-20
EA201301130A1 (ru)	2014-07-30
EP2694510A1 (fr)	2014-02-12
AP3597A (en)	2016-02-19
ES2558780T3 (es)	2016-02-08
EP2694510B1 (fr)	2015-10-14
SG193631A1 (en)	2013-11-29
CU24263B1 (es)	2017-07-04
AP2013007215A0 (en)	2013-10-31
EA024890B1 (ru)	2016-10-31
US9604989B2 (en)	2017-03-28
RS54480B1 (sr)	2016-06-30
US20140113901A1 (en)	2014-04-24
BR112013025777A2 (pt)	2016-12-20
US9206185B2 (en)	2015-12-08
CO6862145A2 (es)	2014-02-10
CN103596957B (zh)	2016-12-07
CU20130135A7 (es)	2014-02-28
JP2014510127A (ja)	2014-04-24
NZ616270A (en)	2015-09-25
CA2832374A1 (fr)	2012-10-11
SMT201600001B (it)	2016-02-25
SI2694510T1 (sl)	2016-02-29
DK2694510T3 (en)	2016-01-18
UY34006A (es)	2012-10-31
KR20140022057A (ko)	2014-02-21
WO2012136776A1 (fr)	2012-10-11
AU2012238589B2 (en)	2017-02-16
GT201300238A (es)	2015-04-06
MA35016B1 (fr)	2014-04-03
UA111739C2 (uk)	2016-06-10
HRP20160011T1 (hr)	2016-02-12
DOP2013000226A (es)	2013-11-15
MX2013011699A (es)	2014-01-31
CN103596957A (zh)	2014-02-19
NI201300105A (es)	2014-07-14
CR20130515A (es)	2013-12-04

Publication	Publication Date	Title
TN2013000400A1 (en)	2015-03-30	Imidazopyridazines as akt kinase inhibitors
MX341456B (es)	2016-08-18	Amino-quinolinas como inhibidores de cinasa.
TN2014000138A1 (en)	2015-09-30	Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
PH12014500373A1 (en)	2019-08-07	Amino quinazolines as kinase inhibitors
EP2566477A4 (fr)	2013-11-20	Amino-quinoléines en tant qu'inhibiteurs de kinase
MX339873B (es)	2016-06-15	Inhibidores de serina/treonina cinasa.
GEP201706745B (en)	2017-10-10	Forms of rifaximin and usage thereof
PH12015500363A1 (en)	2015-04-20	Prodrugs of amino quinazoline kinase inhibitor
MX2015002487A (es)	2015-09-10	Proceso para la preparacion de teneligliptina.
PH12013500554A1 (en)	2013-05-06	Process for preparing pan-cdk inhibitors of the formula (i) and intermediates in the preparation
NZ711192A (en)	2019-04-26	Process for making benzoxazepin compounds
GEP201706626B (en)	2017-02-10	Synthesis of (s)-nifuratel
MX2012014796A (es)	2013-04-03	Proceso para preparar 4-hidroxipiridinas.
EP2882744B8 (fr)	2016-11-09	Procédé de préparation d'inhibiteurs de la c-fms kinase
GB201107985D0 (en)	2011-06-29	Process
AU2013314244A8 (en)	2015-04-30	Novel inhibitor compounds of phosphodiesterase type 10A
AU2013347232A8 (en)	2015-08-06	3-Aminocyclopentane carboxamide derivatives
MX2014009084A (es)	2015-02-05	Derivados de pirimidooxazocina como inhibidores de mtor.
IN2014DN07191A (fr)	2015-04-24
TN2013000128A1 (en)	2014-06-25	Process for preparing pan-cdk inhibitors of the formula (1), and intermediates in the preparation
MY162973A (en)	2017-07-31	New process for the synthesis of agomelatine
UA77456U (ru)	2013-02-11	Способ профилактики гингивита
TN2011000020A1 (en)	2012-09-05	cMET INHIBITORS
UA72478U (ru)	2012-08-27	Применение полентара как средства фригопротекторного действия